Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
American Journal of Respiratory and Critical Care Medicine|January 26, 2013
Exercise-induced pulmonary hypertension: physiological basis and methodological concernsRobert Naeije, Rebecca Vanderpool, Bishnu P Dhakal, et al.
Seminars in Respiratory and Critical Care Medicine|April 1, 2010
Pulmonary arterial hypertension and lung transplantationRajeev Saggar, Joseph P Lynch, John A Belperio, et al.
Seminars in Respiratory and Critical Care Medicine|April 1, 2010
Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatmentS Samuel Weigt, W Dean Wallace, Ariss Derhovanessian, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
A review of exercise pulmonary hypertension in systemic sclerosisFaisal Shaikh, Zafia Anklesaria, Tasneam Shagroni, et al.
Clinical Immunology (Orlando, Fla.)|October 22, 2011
Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosisAnagha A Divekar, Dinesh Khanna, Fereidoun Abtin, et al.
The Annals of Thoracic Surgery|July 2, 2011
Lung transplantation and coronary artery diseaseWilliam Sherman, David G Rabkin, David Ross, et al.
Arthritis and Rheumatism|July 11, 2012
Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot studyRajeev Saggar, D Khanna, S Shapiro, et al.
Chest|December 14, 2018
Right Ventricular Functional Reserve in Early-Stage Idiopathic Pulmonary Fibrosis: An Exercise Two-Dimensional Speckle Tracking Doppler Echocardiography StudyAntonello D'Andrea, Anna Agnese Stanziola, Rajan Saggar, et al.
The Journal of Rheumatology|August 17, 2013
Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohortsHeather Gladue, Virginia Steen, Yannick Allanore, et al.
Arthritis and Rheumatism|July 20, 2011
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung diseaseDinesh Khanna, Rajeev Saggar, Maureen D Mayes, et al.
Pageof 6